# Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis

> **NCT07636057** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Sheikh Zayed Federal Postgraduate Medical Institute** · enrollment: 100 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** JAK inhibitor(tofacitinib/upadacitinib) as advised by the rheumatologist as add on to 25 mg methotrexate

## Key facts

- **NCT ID:** NCT07636057
- **Lead sponsor:** Sheikh Zayed Federal Postgraduate Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-05
- **Primary completion:** 2027-03-05
- **Final completion:** 2027-05-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636057, "Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07636057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*